-
Uncategorized6 months agoNew protein drugs could pave way for faster drug development
A new class of protein drugs have shown amenability to multiple isotopes, paving the way for faster radiopharmaceutical drug development. Biotechnology company Molecular Partners announced preclinical...
-
Uncategorized6 months agoGilead to advance first T cell engager for autoimmune diseases
Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds...
-
Uncategorized6 months ago‘Supercharged’ T cells could improve prostate cancer treatment
Scientists have engineered new ‘supercharged’ immune cells that could attack prostate cancer more effectively. Researchers at UCLA and Stanford Medicine researchers, in collaboration with scientists from the...
-
Uncategorized6 months agoTwelve startups to showcase at SLAS Europe 2026
SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW programme at SLAS Europe 2026 Conference and Exhibition,...
-
Uncategorized6 months agoLilly’s triple agonist significantly reduces A1C and weight
Eli Lilly has announced positive topline results from TRANSCEND-T2D-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1...
-
Uncategorized6 months agoStudy supports Treg enhancement as dementia treatment
A research study led by Dr Alireza Faridar and Dr Stanley Appel at the Houston Methodist Neurological Institute has demonstrated the involvement of the peripheral immune...
-
Uncategorized6 months agoThe next generation of CAR-T cell therapies
Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space. ...
-
Uncategorized6 months agoResearch uncovers how prostate cancer cells resist treatment
Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate cancer cells—an important process that may help explain how some...
-
Uncategorized6 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis has agreed a deal with Synnovation Therapeutics to acquire Pikavation Therapeutics and its portfolio of PI3Kα inhibitor programmes, including SNV4818. Pikavation is a wholly-owned subsidiary...
-
Uncategorized6 months agoLaigo Bio raises $17m to advance oncology pipeline
Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million. Laigo will...
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
Deep dive: Psychedelics back on FDA’s doorstep
‘Patients are not a renewable resource’: Rethinking rare disease R&D
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
